Want to see HK:0512 full AI Analyst Report?
0512 Stock Chart & Stats
HK$7.80
-HK$0.03(-0.67%)
At close: 4:00 PM EST
HK$7.80
-HK$0.03(-0.67%)
Day’s Range― - ―
52-Week RangeHK$4.53 - HK$9.89
Previous CloseN/A
Volume1.96M
Average Volume (3M)9.26M
Market Cap
HK$16.68B
Enterprise ValueHK$20.58B
Total Cash (Recent Filing)HK$2.09B
Total Debt (Recent Filing)HK$4.72B
Price to Earnings (P/E)13.4
Beta0.75
Next Earnings
Aug 12, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield3.13%
Share Statistics
EPS (TTM)0.35
Shares Outstanding3,549,571,000
10 Day Avg. Volume7,622,050
30 Day Avg. Volume9,255,379
Financial Highlights & Ratios
PEG Ratio-0.45
Price to Book (P/B)1.62
Price to Sales (P/S)2.24
P/FCF Ratio35.50
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.46
Revenue Forecast (FY)HK$13.73B
Bulls Say, Bears Say
Bulls Say
Steady Revenue GrowthConsistent top-line growth across 2021–2025 signals durable end-market demand and successful commercialization. This steady revenue base supports longer-term R&D payback, predictable production planning, and reduces reliance on one-off product wins, improving multi-quarter cash visibility.
Moderate Leverage And Growing Equity BaseLow debt-to-equity and rising equity provide financial flexibility for sustained R&D, M&A or capex without severe solvency risk. A moderate leverage profile limits interest burden and supports resilience through industry cycles, preserving capacity to fund strategic investments.
Diversified Pharma And Medical-device Business ModelOperating across drugs and medical devices diversifies revenue streams and commercialization routes, lowering single-product dependency. This structural mix aids cross-selling to hospitals and insurers and can stabilize margins as device and pharma cycles differ over multiple quarters.
Bears Say
Sharp Profitability Decline In 2025A near-halving of net and operating margins materially reduces the company's earnings power and return on capital. If driven by structural cost, pricing, or mix shifts, this deterioration limits reinvestment capacity and may persist absent sustained margin-restoration measures.
Weakened Cash Conversion And Lower FCF CoverA sharp drop in FCF and lower coverage of net income constrains funding for R&D, capex, dividends or M&A. Reduced cash conversion raises earnings-quality and liquidity concerns, increasing reliance on external funding if investments or payouts remain unchanged.
Gross Margin CompressionMaterial gross margin erosion points to pricing pressure, unfavorable product mix, or rising input costs. Persistent gross margin weakness constrains operating leverage and makes margin recovery harder, pressuring long-term profitability unless cost or portfolio actions are taken.
Grand Pharmaceutical Group Limited News
0512 FAQ
What was Grand Pharmaceutical Group Limited’s price range in the past 12 months?
Grand Pharmaceutical Group Limited lowest stock price was HK$4.53 and its highest was HK$9.89 in the past 12 months.
What is Grand Pharmaceutical Group Limited’s market cap?
Grand Pharmaceutical Group Limited’s market cap is HK$16.68B.
When is Grand Pharmaceutical Group Limited’s upcoming earnings report date?
Grand Pharmaceutical Group Limited’s upcoming earnings report date is Aug 12, 2026 which is in 42 days.
How were Grand Pharmaceutical Group Limited’s earnings last quarter?
Grand Pharmaceutical Group Limited released its earnings results on Mar 26, 2026. The company reported HK$0.02 earnings per share for the quarter, beating the consensus estimate of N/A by HK$0.02.
Is Grand Pharmaceutical Group Limited overvalued?
According to Wall Street analysts Grand Pharmaceutical Group Limited’s price is currently Overvalued.
Does Grand Pharmaceutical Group Limited pay dividends?
Grand Pharmaceutical Group Limited pays a Annually dividend of HK$0.169 which represents an annual dividend yield of 3.13%. See more information on Grand Pharmaceutical Group Limited dividends here
What is Grand Pharmaceutical Group Limited’s EPS estimate?
Grand Pharmaceutical Group Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Grand Pharmaceutical Group Limited have?
Grand Pharmaceutical Group Limited has 3,549,571,000 shares outstanding.
What happened to Grand Pharmaceutical Group Limited’s price movement after its last earnings report?
Grand Pharmaceutical Group Limited reported an EPS of HK$0.02 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -1.212%.
Which hedge fund is a major shareholder of Grand Pharmaceutical Group Limited?
Currently, no hedge funds are holding shares in HK:0512
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Grand Pharmaceutical Group Limited Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
87.42%
12-Months-Change
Fundamentals
Return on Equity
7.26%
Trailing 12-Months
Asset Growth
8.71%
Trailing 12-Months
Company Description
Grand Pharmaceutical Group Limited
Grand Pharmaceutical Group Limited, an investment holding company, engages in the research and development, manufacture, and sale of pharmaceutical preparations and medical devices, biotechnology and healthcare products, and pharmaceutical raw materials. The company offers respiratory, ophthalmology, cerebro-cardiovascular emergency, and biotechnology related products. It manufactures and sells pharmaceutical, taurine, agrochemicals, chemical medicine, and amino acid series products. In addition, the company provides bio-pesticides and additives; disposal surgical products; and Chinese medicine and health food products, as well as engages in the treatment of sewage. The company has a strategic cooperation agreement with the Eye Hospital of Wenzhou Medical University in the field of ophthalmic drug research and development. It operates in the People's Republic of China, the rest of Asia, the United States, Europe, and internationally. The company has a business collaboration with the Sirtex Group agreement to enable collaboration on research and development of pharmaceutical products. The company has a strategic partnership with the University of Hong Kong for the research and development of drugs in the field of anti-infection and the industrialization of the research results. The company was formerly known as China Grand Pharmaceutical and Healthcare Holdings Limited. The company was incorporated in 1995 and is based in Central, Hong Kong.
Technical Analysis
China Medical System Holdings
―
Guangzhou Baiyunshan Pharmaceutical Holdings Company
―
Livzon Pharmaceutical Group
―
China Resources Pharmaceutical Group Ltd.
―
Consun Pharmaceutical Group Ltd.
―
Options Prices
Currently, No data available
---